Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 13/20 | 0.53 |
| ▸ | CFTR | P13569 | 1/20 | 0.47 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202620 | 1.00 | PDK2 (0.53) | PDK2CFTRGOPCALDH1A1MEN1 | |
| SCHEMBL10550632 | 0.83 | PDK2 (0.41) | PDK2CFTRGOPCALDH1A1MEN1 | |
| SCHEMBL11241768 | 0.83 | CFTR (0.46) | PDK2CFTRGOPCALDH1A1MEN1 | |
| SCHEMBL11833065 | 0.83 | CFTR (0.46) | CFTRGOPCALDH1A1MEN1LMNA | |
| SCHEMBL24517455 | 0.80 | PDK2 (0.53) | PDK2ALDH1A1MAPTAKR1C1HSP90AA1 | |
| SCHEMBL29618364 | 0.80 | PDK2 (0.53) | PDK2ALDH1A1MAPTAKR1C1HSP90AA1 | |
| SCHEMBL29618362 | 0.80 | PDK2 (0.53) | PDK2ALDH1A1MAPTAKR1C1HSP90AA1 | |
| SCHEMBL28758440 | 0.78 | PDK2 (0.46) | PDK2TDP1 | |
| Acetic Acid SCHEMBL9529245 | 0.78 | CFTR (0.45) | PDK2CFTRGOPCALDH1A1MEN1 | |
| SCHEMBL11832018 | 0.76 | CFTR (0.40) | CFTRGOPCALDH1A1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120137900-A | Method for selectively removing undifferentiated pluripotent stem cells | 佛教慈济医疗财团法人 | 2025-06-13 | — | — | CN | claimed |
| US-20250188411-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2025-06-12 | — | — | US | claimed |
| EP-4570901-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | Buddhist Tzu Chi Medical Foundation (TW) | 2025-06-18 | — | — | EP | disclosed |
| CN-120137900-A | Method for selectively removing undifferentiated pluripotent stem cells | 佛教慈济医疗财团法人 | 2025-06-13 | — | — | CN | disclosed |
| US-20250188411-A1 | METHOD FOR SELECTIVE REMOVAL OF UNDIFFERENTIATED PLURIPOTENT STEM CELLS | BUDDHIST TZU CHI MEDICAL FOUNDATION (TW) | 2025-06-12 | — | — | US | disclosed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | disclosed |
| EP-4452265-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | Augustine Therapeutics (BE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118507-A2 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2023-06-29 | — | — | WO | disclosed |
| US-20150056702-A1 | METHOD AND KIT FOR CULTURING STEM CELLS | UNIV CHINA MEDICAL (TW) | 2015-02-26 | — | — | US | disclosed |
| US-20140212970-A1 | METHOD AND KIT FOR CULTURING STEM CELLS | CHINA MEDICAL UNIVERSITY (TW) | 2014-07-31 | — | — | US | disclosed |
| US-4855460-A | ZINC OR CADMIUM CATALYST | RHONE-POULENC CHIMIE (FR) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | PDK2 1463/4885CFTR 3061/4885GOPC 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.